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Abstract 
Background: Brain-derived neurotrophic factor (BDNF) exerts beneficial effects not only on diabetic neuropathies 
but also on cardiovascular injury. There is argument regarding the levels of serum BDNF in patients with diabetes mel-
litus (DM). Because BDNF in peripheral blood is rich in platelets, this may represent dysregulation of BDNF release from 
platelets. Here we focused on advanced glycation end products (AGEs), which are elevated in patients with DM and 
have adverse effects on cardiovascular functions. The aim of this study is to elucidate the role of AGEs in the regula-
tion of BDNF release from human platelets.
Methods: Platelets collected from peripheral blood of healthy volunteers were incubated with various concentra-
tions of AGE (glycated-BSA) at 37 °C for 5 min with or without BAPTA-AM, a cell permeable Ca2+ chelator, or PP2, a 
potent inhibitor of Src family kinases (SFKs). Released and cellular BDNF were measured by ELISA and calculated. Phos-
phorylation of Src and Syk, a downstream kinase of SFKs, in stimulated platelets was examined by Western blotting 
and immunoprecipitation.
Results: AGE induced BDNF release from human platelets in a dose-dependent manner, which was dependent on 
intracellular Ca2+ and SFKs. We found that AGE induced phosphorylation of Src and Syk.
Conclusions: AGE induces BDNF release from human platelets through the activation of the Src-Syk-(possibly phos-
pholipase C)-Ca2+ pathway. Considering the toxic action of AGEs and the protective roles of BDNF, it can be hypoth-
esized that AGE-induced BDNF release is a biological defense system in the early phase of diabetes. Chronic elevation 
of AGEs may induce depletion or downregulation of BDNF in platelets during the progression of DM.
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Background
Brain-derived neurotrophic factor (BDNF) is a mem-
ber of the neurotrophin family and plays essential roles 
in differentiation and survival of central and peripheral 
neurons [1]. Thus, BDNF has been implicated in neuro-
degenerative diseases and has been tried as a therapeutic 
intervention for such diseases [2]. In addition to these 
classic neurotrophic actions, BDNF regulates synap-
tic plasticity in the brain [3, 4]. Because of its effects on 
functional alterations in the central nervous system, it 
was implicated in psychiatric diseases such as depression 
[5]. Another face of BDNF has been emerging, which is 
the regulation of food intake and energy metabolism [6, 
7]. The involvement of BDNF in diabetes has been stud-
ied from those aspects [8].
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Diabetes mellitus (DM) is associated with macro-
vascular complications, including increased risks of 
coronary heart disease, stroke and amputation, and 
microvascular complications, such as nephropathy, 
retinopathy and neuropathy. In addition to its benefi-
cial effects on neuropathies [9] and retinopathies [10], 
the cardiovascular protective effects of BDNF were 
reported. BDNF was shown to prevent or ameliorate 
myocardial infraction [11] and to promote revascu-
larization after ischemic injury [12]. Furthermore, 
the association of blood BDNF levels with cardiovas-
cular diseases, such as angina pectoris [13] and heart 
failure [14, 15] were reported, with lower levels of 
BDNF being associated with the risk of cardiovascular 
diseases.
These effects must come from outside of the CNS, 
presumably from BDNF in blood. Both increased [16, 
17] and decreased [18–20] BDNF were reported in 
blood of patients with DM. The mechanism of this 
inconsistency remains unclear although blood glucose 
levels, duration of DM, medications, gender, etc., may 
play a role.
Platelets are the major source of BDNF in human 
blood, at least under physiological conditions [21, 22], 
which may indicate that serum BDNF levels reflect the 
amount released from platelets. Although the causal-
ity and mechanisms remain unclear, it is possible that 
the dynamics of BDNF release are dysregulated in dia-
betes patients, thus altering serum levels. Therefore, 
we investigated the acute BDNF release from plate-
lets from healthy individuals. BDNF is known to be 
released from platelets in response to certain stimu-
lants such as thrombin [22]. Thus, we examined the 
effects of molecules that are abundant in the blood 
of DM patients and whose receptors are expressed in 
platelets.
We focused on advanced glycation end products 
(AGEs). AGEs are a group of carbonyl compounds 
produced by the non-enzymatic reaction of reduc-
ing sugars and amino groups of proteins, lipids and 
nucleic acids, which is called the Maillard reaction [23]. 
AGE levels are high in blood of patients with diabetes 
because of their chronic hyperglycemia [23], and AGE 
accumulation induces adverse effects on endothelial 
cells [24] and cardiovascular systems [25]. Their recep-
tors, such as receptors for AGE (RAGE) [26], CD36 [27] 
and 5HT2A/C receptor [28], are expressed in human 
platelets.
To analyze the dynamics of acute BDNF release from 
platelets under physiological conditions, we examined 
the effect of AGEs on BDNF release from platelets of 
healthy control participants (non-diabetic) and ana-
lyzed their signaling mechanisms.
Methods
Materials
Glycated-BSA, used as the AGE in this study, was pur-
chased from Bio Vision. Human thrombin was obtained 
from Sigma-Aldrich. Prostaglandin E1 (PGE1), anti-c-Src 
and anti-phospho-Src antibodies were purchased from 
Santa Cruz Biotechnology. BAPTA-AM and PP2 were 
obtained from Dojin and Abcam, respectively. Anti-Syk 
antibody and anti-phosphotyrosine antibody (PY100) 
were purchased from Cell Signaling Technology.
Preparation of platelet samples, serum and whole blood
The Ethics Committee of Niigata University approved the 
study and informed consent was obtained from partici-
pants. Blood was collected from healthy volunteers aged 
31–53  years according to the method described previ-
ously [29]. Briefly, venous blood was collected using a 
22 gauge needle and was transferred to a tube contain-
ing 3.2% sodium citrate. Platelet-rich plasma (PRP) was 
obtained by centrifugation at 200×g for 10 min at room 
temperature. Acid citrate dextrose solution (ACD) con-
taining PGE1 (1 μM) was added to PRP at a final concen-
tration of 15% and then washed twice with Tris/EDTA/
saline buffer (10 mM Tris, 1 mM EDTA, 150 mM NaCl, 
pH 7.5) containing PGE1. Platelets were finally diluted 
in Ca2+ -free tyrode buffer (138 mM NaCl, 2.7 mM KCI, 
1  mM MgCl2, 3  mM NaH2PO4, 5  mM glucose, 10  mM 
HEPES, pH 7.4). Platelet samples (1 ×  108 cells/500  μl) 
were incubated with the indicated agents at 37  °C for 
5 min.
BAPTA-AM or PP2 was added 5 min prior to the AGE 
stimulation. Platelet activation was stopped by adding 
cold EDTA solution (1 mM) and the mixture was imme-
diately centrifuged at 800×g for 10  min. The superna-
tants were collected and the residual pellet was lysed with 
lysis buffer (20  mM NaH2PO4 2  mM 2  mM NaH2PO4, 
150 mM NaCl 0.5% Triton-X100: pH 7.5) containing pro-
tease and phosphatase inhibitor cocktails (cOmplete and 
PhosStop, Roche). All procedures using platelets were 
performed under sterile conditions.
Whole blood samples were prepared by dissolving 
them in lysis buffer and sonication. After centrifugation 
at 15,000×g for 5  min, the supernatant was collected. 
Serum was prepared by incubating blood at 37 °C for 1 h 
and centrifuging at 800×g for 10 min. The supernatants 
were collected as serum samples. All samples were stored 
at −80 °C until use.
Measurements of BDNF, PF4 and 5‑HT
The concentrations of BDNF in serum, whole blood, 
platelet supernatant and platelet lysate were measured 
by BDNF ELISA according to the reported protocol 
[30]. Quantitative assays for platelet factor 4 (PF4) were 
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performed by ELISA according to the manufacturer’s 
instructions (R&D). 5-hydroxytryptamine(5-HT) was 
measured by high performance liquid chromatography 
with electrochemical detection as described Previously 
[31].
Calculation of released molecules from platelets
The levels of released BDNF, PF4 and 5-HT from plate-
lets were represented as percentages of their content in 
platelets according to the following formula: percentage 
of release =  (amount released from agonist-stimulated 
platelets)/(amount released from agonist- stimulated 
platelets + amount of platelet lysate) × 100.
Western blot analysis and immunoprecipitation
Samples for Western blotting and immunoprecipitation 
were prepared under the same conditions as for the 
release assay, and analyses were performed essentially 
as reported [32]. Briefly, platelets (5 × 108 cells/300 μl) 
were lysed and sonicated in sample buffer (10  mM 
Tris–HCl, 150  mM NaCl, 2% SDS, cOmplete, PhosS-
top). Equal amounts of protein were subjected to 10% 
sodium dodecyl sulfate-polyacrylamide gel electropho-
resis and transferred to PVDF membranes. The mem-
branes were incubated with primary antibodies and 
then with secondary antibodies (DAKO; 1:10,000). Per-
oxidase activity was visualized with a chemilumines-
cent reagent (Immunostar: Wako) and G:Box apparatus 
(Syngene). Quantification was performed by GeneSys 
software (Syngene). For immunoprecipitation [32], 
platelets (5 × 108 cells/300 μl) were lysed and sonicated 
in RIPA buffer (50 mM Tris/HCI, 150 mM NaCI, 1 mM 
EDTA, 5  mM EGTA, 1% NP-40, 20  mM glycerophos-
phate, 0.5 M DTT) containing cOmplete and PhosStop. 
After centrifugation, supernatants were preabsorbed 
with protein G-Sepharose (GE Healthcare). Superna-
tants were then incubated with anti-Syk antibodies 
overnight at 4 °C and the immunocomplexes were pre-
cipitated by the addition of 40 μl of Protein GSepharose 
for 2 h. After brief centrifugation, immunoprecipitates 
were washed 3 times with RIPA buffer and used for 
Western blotting.
Statistical analysis
Data are expressed throughout as mean ± SEM. Statisti-
cal significance was determined using the Student’s t test 
for comparisons of two groups and one-way or two-way 
ANOVA for multiple comparisons. Tukey’s test was used 
for post hoc comparison when the F value was significant 
(p < 0.05).
Results
Levels of BDNF had large individual differences but the 
ratio of release was constant
The levels of BDNF in whole blood, serum and plate-
lets from individuals as measured by ELISA are shown 
in Additional file  1: Figure S1. Ten healthy volun-
teers (8 men and 2 women) were examined. Mean 
age was 38.8 ±  2.4 years and mean blood glucose was 
106 ± 12.2 mg/dl (data were presented as mean ± SD). 
Other information on blood data is provided in Addi-
tional file  2: Table S1. None of the blood indices were 
correlated with BDNF content in whole blood, serum 
or platelets.
Although the contents in each fraction varied greatly 
among participants, the ratio of BDNF release from 
platelets was rather constant as shown in Fig.  1 (see 
also Additional file  3: Figure S2). Thus, BDNF release 
in response to stimulation in different individuals was 
analyzed in this study.
Before the main experiments, the assay system was 
validated by using thrombin, previously reported as a 
secretagogue of BDNF from platelets, as a positive con-
trol. As reported previously [22], thrombin strongly 
induced BDNF release (control: 30.2 +  24.4  pg/100  μl 
vs. 0.1 U/ml thrombin 321 + 192.9 pg/100 μl).
AGE, not high glucose or mannitol, induced BDNF release 
from human platelets
Since the validity of the assay system was guaranteed, 
the effects of high glucose, mannitol and AGE on BDNF 
release from platelets were examined because hyper-
glycemia is the primary manifestation of diabetes. We 
used mannitol as the osmolarity control and AGE as a 
Fig. 1 AGE, but not high glucose and high mannitol, induced BDNF 
release from platelets. Each platelet sample (1 × 108 cells/tube) was 
incubated with Ca2+-free tyrode buffer containing 0.1% BSA (C, con-
trol), 25 mM glucose (G), 25 mM mannitol (M) and 100 μg/ml AGE (A) 
for 5 min at 37 °C (n = 8). Data are presented as the ratio of released 
BDNF/(released BDNF + BDNF content) (mean ± SEM). Statistical 
analysis was performed by one-way ANOVA. *p < 0.05 vs. control
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representative of chronic hyperglycemia. Neither high 
glucose nor mannitol but AGE, glycated-BSA in this 
study, significantly induced BDNF release (Fig. 1). The 
action of AGE on BDNF release was dose-dependent 
(Fig.  2) and was saturated at a dose of 100  μg/ml up 
to 1 mg/ml (Additional file 3: Figure S2). The effect of 
AGE was rather acute (5  min) (Fig.  1). Although AGE 
tended to increase BDNF release even at 20 and 60 min, 
a significant increase was only observed at 5 min after 
stimulation (Additional file 4: Figure S3). AGE, even at 
the maximum dose we used in this study, did not have 
an acute toxic effect on platelets.
To further analyze the role of AGE as a secretion-
inducing substance for platelets, the release of PF4 and 
5-HT, contained in alpha- and dense granule vesicles, 
respectively, was examined. Whereas AGE induced PF4 
release in a manner similar to BDNF release, it had little 
effect on 5-HT release, although the effect was significant 
(see Additional file 5: Figure S4). The results suggest that 
the AGE-evoked release under this assay condition was 
rather specific for the alpha granule component.
AGE‑induced BDNF release was intracellular 
Ca2+ ‑dependent
A variety of agonists induce the elevation of cytosolic 
Ca2 + in platelets by enhancing the release of Ca2+ from 
the intracellular store, an event that plays a crucial role in 
platelet function [33]. AGE has been reported to increase 
cytosolic Ca2+ in mouse cardiomyocytes [34] and human 
platelets [35]. Thus, the Ca2+  -dependency of BDNF 
release was examined. Because the assay buffer did not 
contain Ca2+ (extracellular Ca2+ -free condition), the role 
of intracellular Ca2+ on AGE-induced BDNF release was 
analyzed using BAPTA-AM, a cell permeable Ca2+ che-
lator. The concentration of BAPTA-AM (10  μM) was 
determined according to previous reports [36, 37].
BAPTA-AM completely abolished the effect of AGE on 
BDNE release (Fig. 3), indicating that intracellular Ca2+ is 
essential for this phenomenon. We also confirmed that 
AGE (100  μg/ml) increased intracellular Ca2+  levels at 
3 min after stimulation by using Oregon Green (Thermo 
Fisher) indicator (Additional file 6: Figure S5).
AGE‑induced BDNF release was dependent on Src family 
kinases (SFKs)
To further analyze the signaling mechanism, involvement 
of the SFKs was examined. The reasons for this analysis 
were that (1) platelets express a high level of Src (0.2–
0.4% of total proteins) [38], (2) AGEs activate Src [39], (3) 
SFKs physically interact with CD36 [40] and 4) SFKs are 
linked to the increase in intracellular Ca2+  through the 
Syk-phospholipase Ca2+—IP3 pathway [41]. Thus, the 
effects of PP2, a potent inhibitor of SFKs, were examined. 
PP2 completely inhibited the effect of AGE on BDNF 
release (Fig. 4), while it had a moderate suppressive effect 
on thrombin-induced release (thrombin: 46.9  ±  5.2 vs. 
thrombin  +  PP2: 42.7  ±  13.0; an approximately 0.9% 
reduction).
To confirm whether AGE actually activates Src in human 
platelets, Western blotting was performed. As expected, 
AGE rapidly induced the phosphorylation of Src at Tyr416 
and that action was blocked by PP2 (Fig. 5). Furthermore, 
phosphorylation of Syk, a downstream kinase of SFKs, was 
also induced by AGE and inhibited by PP2 as revealed by 
immunoprecipitation-Western blotting analysis (Fig.  6). 
Those results suggest that AGE activates SFKs and then 
activates Syk to increase intracellular Ca2+ .
Discussion
Reports of serum BDNF levels in patients with DM have 
been controversial. In comparison with non-diabetic 
individuals, some studies found that serum BDNF lev-
els in patients with DM were lower [18–20] while others 
found higher values [16, 17].
Because the major origin of BDNF in blood is platelets 
[21, 22 also see Additional file  1: Figure S1, Additional 
file  2: Table S1], alterations in BDNF levels may be the 
result of dysregulation of BDNF release from platelets. 
Therefore, we examined the acute effects of high glucose, 
a primary indication of DM, and AGE, which are result-
ant products of chronic hyperglycemia.
Here, we revealed that AGE, a glycated-BSA in this 
study, induced BDNF release from human platelets 
through intracellular Ca2+ elevation possibly via the Src-
Syk pathway.
Fig. 2 AGE induced BDNF release from platelets in a dose-
dependent manner. After platelet samples (1 × 108 cells/tube) were 
incubated at 37 °C by stimulations with 0.1% BSA (control), 25, 50 and 
100 μg/ml AGE for 5 min, the supernatants and lysates were collected 
and BDNF contents were measured by ELISA (n = 10). Data were 
presented as the ratio of released BDNF/(released BDNF + BDNF con-
tent) (mean ± SEM). Statistical analysis was performed by one-way 
ANOVA. *p < 0.05 vs. control
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AGEs are heterogeneous carbonyl compounds that are 
formed by the Maillard reaction between reducing sug-
ars and the amino groups of protein, lipids and nucleic 
acids. Because of the chronic hyperglycemia in diabetic 
patients, AGE accumulation in blood is accelerated in 
those individual [42]. AGE accumulation correlated with 
microvascular lesions that cause diabetic retinopathy 
[43] or nephropathy [44]. In addition, AGE was reported 
to enhance aggregation and activation of platelets [35]. 
These abnormal platelets may be related to the risk of 
the development of cardiovascular complications [45]. 
Results of a clinical study also supported the concept 
that high AGE in diabetes mellitus is related to the risk of 
peripheral arterial diseases [46].
The deleterious action on endothelial cells by AGEs 
is mediated by their receptors. While many receptors 
for AGEs have been identified, the receptor for AGEs 
(RAGE) is the most characterized. Upon binding of 
AGEs to the RAGE, a variety of downstream responses 
occur, such as production of reactive oxygen species and 
expression of cytokines, cell adhesion molecules, etc. 
that lead to cellular insults [47]. While the expression of 
RAGE [26] as well as CD36 [27] and 5HT2A/C recep-
tor [28] were reported on the platelet surface, it remains 
which (or all) receptors are responsive to AGE for BDNF 
release.
BDNF is a neurotrophic factor promoting differen-
tiation and survival and modulating synaptic plasticity 
in central and peripheral neurons through its cognate 
receptor TrkB. Outside of the nervous system, TrkB 
expression was reported in several cell types such as 
immune [48], pancreatic alpha [49], endothelial [50] and 
myocardial [51] cells. In contrast to AGEs, BDNF was 
shown to exert a protective action on these cells [12, 52]. 
Exogenous BDNF induced vasodilatation and protected 
against vascular injury and thrombus formation in the 
walls of cerebral arteries [53] and also was noted to act 
on revascularization [12]. Clinical observations showed 
that low blood BDNF levels are associated with a high 
risk of heart failure [14, 15, 54]. Thus, regulated release 
of BDNF from platelets may be an important mechanism 
for maintaining cardiovascular homeostasis.
Mechanism of BDNF release has been well char-
acterized in neuronal cells. BDNF is released in an 
activity‒dependent manner; in other words, depolariza-
tion-induced Ca2+  influx triggers its release [55]. Other 
studies showed that an increase in cytosolic Ca2+ derived 
from intracellular Ca2+ stores is sufficient for BDNF 
release [56]. These results indicate that the increase in 
intracellular Ca2+, whether it comes from an extracellu-
lar space or intracellular stores, induces BDNF release. 
Thus, Ca2+-dependency of BDNF release from platelets 
was examined. In the present study, Ca2+  ions were not 
included in the assay buffer to avoid basal platelet acti-
vation. Ca2+-dependency was analyzed by using BAPTA-
AM, a cell permeable Ca2+-chelator. BAPTA-AM 
completely inhibited AGE-induced BDNF release, sug-
gesting that the BDNF release mechanism is rather com-
mon among different cell types.
Similar to other growth factors, BDNF is contained in 
α-granules of platelets [57]. To determine the action of 
AGE on alpha-granules, release of another molecule in 
these granules was examined. AGE induced the release 
Fig. 3 BAPTA-AM completely inhibited AGE-induced BDNF release 
from platelets. Platelet samples (1 × 108 cells/tube) were pretreated 
with or without 10 μM BAPTA-AM for 5 min, then 100 μg/ml AGE was 
added to the samples for 5 min. Data were presented as the ratio 
of released BDNF/(released BDNF + BDNF content) (mean ± SEM). 
Statistical analyses were performed by SPSS two-way ANOVA with 
post hoc test. White bars control (0.1% BSA), black bars AGE (100 μg/
ml). *p < 0.05 for indicated comparisons
Fig. 4 PP2 completely inhibited AGE-induced BDNF release from 
platelets. Platelets (1 × 108 cells/tube) were pretreated with or 
without 10 μM PP2 for 5 min, then 100 μg/ml AGE was added to 
the samples for 5 min. Data were presented as the ratio of released 
BDNF/(released BDNF + BDNF content) (mean ± SEM). Statistical 
analyses were performed by SPSS two-way ANOVA with post hoc 
test. White bars control (0.1% BSA), black bars AGE (100 μg/ml). In this 
figure, an interaction between AGE-PP2 was not detected. *p < 0.05 
for indicated comparisons
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of PF4, one of the contents of alpha-granules. Although 
AGE significantly increased the release of 5-HT in dense 
granules, the ratio to its total content was quite low 
(Additional file  3: Figure S2). This suggests that under 
extracellular Ca2+-free conditions, 5-HT release is not 
sufficiently driven by a particular stimulation.
How is Ca2+  released from intracellular stores? We 
examined the roles of SFKs because a previous study 
indicated that there were high levels of Src in platelets 
[38] and that SFKs were involved in in AGE-induced 
signaling. In addition, activation of SFKs was shown to 
lead to an increase in intracellular Ca2+ [41, 58]. AGE was 
reported to induce Src activation in vascular endothe-
lial cells through RAGE [39]. CD36, another receptor 
for AGE, interacted with Fyn, Lyn and Yes, members 
of SFKs in platelets [40]. Thus, whether the inhibitor of 
kinases suppresses the effect of AGE was analyzed. PP2, 
a potent Src family kinase inhibitor, completely blocked 
the AGE-induced BDNF release. The results suggest that 
Src and/or other members of the family kinases are acti-
vated by AGE in human platelets. Indeed, western blot 
analysis using phospho-Src antibody showed that AGE 
increased the phosphorylation of Src (Fig.  5). Although 
a comprehensive investigation is awaited, other mem-
bers of SFKs may be involved in the process of BDNF 
release. In B-cells, Lyn, a member of SFKs, phosphoryl-
ates and activates Syk, which induces Ca2+  release from 
the stores through phospholipase Cγ (PLCγ)-IP3 [41]. 
Syk was shown to be activated in platelets and increase 
intracellular Ca2+ in response to stimuli [58]. AGE actu-
ally induced phosphorylation of Syk (Fig. 6). It was inhib-
ited by PP2, suggesting that it occurred downstream of 
SFKs after AGE stimulation. Thus, the results obtained in 
this study suggest that AGE activates SFKs, at least Src, 
and that downstream Syk then increases intracellular 
Ca2+ possibly through PLCγ-IP3 activation.
Considering the toxic action of AGEs and protec-
tive roles of BDNF, it can be hypothesized that AGE-
induced BDNF release is a biological defense system 
in the early phase of diabetes when the levels of AGEs 
are becoming higher. To protect against AGE-induced 
damage to, for example, vascular endothelial cells, 
platelets release BDNF to protect these cells in an early 
phase of the disease. However, a chronic elevation 
Fig. 5 AGE induces Src phosphorylation in platelets. a Western blot 
analysis of phosphor-Src (Tyr416) and total c-Src after a 5-min stimula-
tion of 100 μg/ml AGE with or without 10 μM PP2. b The graph shows 
quantification of the P-Src/Total Src ratio. Data are presented as fold 
changes compared to the control (n = 4, mean ± SEM). White bars 
control, black bars AGE (100 μg/ml). Statistical analysis was performed 
by SPSS two-way ANOVA with post hoc test (n = 4). *p < 0.05 for 
indicated comparisons
Fig. 6 AGE induced Syk phosphorylation in platelets. a Immunopre-
cipitation-western blot analysis of Syk phosphorylation after a 5-min 
stimulation of 100 μg/ml AGE with or without 10 μM PP2. Samples 
were immunoprecipitated with and Syk antibody, then western blot-
ting with anti-phospho tyrosine antibody (PY100). b The graph shows 
quantification of the P-Syk/Total Syk ratio. Data are presented as fold 
changes compared to the control (n = 4, mean ± SEM). Statistical 
analyses were performed by SPSS two-way ANOVA with post hoc 
test. *p < 0.05 for indicated comparisons
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of AGEs may induce depletion or downregulation of 
BDNF in platelets during the progression of DM. Actu-
ally, a recent report supported this idea. While the 
serum BDNF levels are higher in prediabetic or early 
diabetic individuals than in normoglycemic persons, 
the serum BDNF levels are lower in patients with long-
standing DM than in normal controls [16]. Thus, at 
least one causative factor in the breakdown of serum 
BDNF homeostasis in DM patients seems to be due to 
the accumulation of AGEs in the blood.
Conclusions
AGE induces BDNF release from human platelets 
through the activation of the SrcSyk-(possibly phospho-
lipase C)-Ca2+  pathway. Considering the toxic action of 
AGEs and the protective roles of BDNF, it can be hypoth-
esized that AGE-induced BDNF release is a biological 
defense system in the early phase of diabetes. Chronic 
elevation of AGEs may induce depletion or downregula-
tion of BDNF in platelets during the progression of DM.
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Additional file 1: Figure S1. Scatter plot of BDNF levels in whole blood, 
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was analyzed at SRL. The homeostasis model assessment of insulin resist-
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Figure S2. BDNF release at higher AGE concentrations (100 μg–1 mg/
ml AGE). Data are presented as means ± SEM (n = 8). Statistical analyses 
were performed by SPSS one-way ANOVA. *p < 0.05 vs control. Note that 
100 mg/ml was the saturation dose. Figure S3. Time course of AGE-
induced BDNF release. BDNF release was measured at 5, 20 and 60 min 
after AGE stimulation. White bar, control; light grey bar, 25 μg/ml AGE; dark 
grey bar, 50 μg/ml AGE; black bar, 100 μg/ml AGE (n = 8, means ± SEM). 
Statistical analysis was performed by one-way ANOVA. *p < 0.05 vs con-
trol. The graph at 5 min is same as Fig. 2. Figure S4. AGE induced PF4 and 
5-HT release from human platelets. Data were presented as means ± SEM 
(n = 8). Statistical analysis were performed by SPSS paired t test. White 
bars, control; black bars, AGE (100 μg/ml). *p < 0.05 vs control. Figure S5. 
AGE increased intracellular Ca2+ levels in platelets. Platelet was incubated 
with Oregon Green 488 (2 mM, Thermo Fisher) for 30 min and was washed 
with assay buffer (same as BDNF assay buffer). (a), Fluorescent intensity 
was measured by fluorescent microplate reader (Ex: 490 nm, EM: 530 nM) 
3 min after AGE stimulation according to the manufacture’s instruction. 
Data are presented as means ± SEM (n = 30 (well)). Typical fluorescent 
photomicrographs of control (b) and AGE-treated (c) platelets.
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